公司概述
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of chimeric antigen receptor cell therapy targeting light chain Amyloidosis and immune-mediated diseases within the United States and Australia. The company functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high-risk research and development phases prior to commercial product launches. Its current market capitalization stands at $516.87M, while annual revenue and employee count are not disclosed in the provided data, reflecting the typical profile of a pre-revenue or early-stage biotech firm. This market cap valuation indicates that the company's value is derived almost entirely from its intellectual property pipeline and potential future commercialization prospects rather than established historical cash flows or sales performance.
财务健康
The company reported net income of $-29,438,612 and EBITDA of $-29,710,668 for the trailing twelve months, with revenue figures not available, suggesting a stage where operational losses are expected to fund ongoing clinical trials. The gap between revenue and net income is not directly calculable due to missing revenue data, but the significant negative net income relative to EBITDA highlights the substantial non-operating costs or one-time expenses impacting the bottom line. Free cash flow stands at $-13,612,449, indicating a cash burn rate that necessitates continuous capital raising to maintain operations and advance its lead product NXC-201. Gross margin, operating margin, and profit margin are all recorded at 0.0%, which is consistent with early-stage biotechnology companies that have not yet generated meaningful commercial sales to offset high development expenditures. The company holds $100.41M in cash against total debt of $1.07M, resulting in a debt-to-equity ratio of 1.14, which suggests a balance sheet structure where equity is leveraged relative to liabilities despite the low absolute debt level. A current ratio of 10.01 demonstrates robust short-term liquidity, providing ample coverage for immediate obligations and operational runway. Return on Equity is -55.0% and Return on Assets is -29.3%, metrics that reveal management is currently utilizing shareholder capital to pursue high-risk, high-reward development goals rather than generating immediate financial returns.
估值评估
The trailing P/E ratio is not available due to negative earnings, while the forward P/E is listed at -13.40, implying that the market is pricing in future earnings recovery or continued losses depending on the trajectory of clinical milestones. The price-to-book ratio stands at 5.51, indicating that the market values the company at a significant premium over its book value, reflecting expectations of high future growth potential or valuable intangible assets not fully captured on the balance sheet. Price-to-sales ratio and EV/EBITDA are not applicable in standard positive terms given the financial profile, with the EV/EBITDA standing at -14.04, further emphasizing the pre-profitability status where valuation relies on cash reserves and pipeline potential. The stock has traded between a 52-week high of $11.61 and a 52-week low of $1.34, with the current price position relative to this range dependent on the specific trading day but generally reflecting the high volatility inherent in biotech stocks. A beta of 0.21 suggests that the stock exhibits significantly lower volatility relative to the broader market, moving less than one-fifth as much as the market index in either direction.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, which is typical for clinical-stage companies where revenue is often negligible or non-existent during the development phase. Consequently, the comparison between earnings and revenue growth rates cannot be quantified, but the absence of positive growth metrics indicates the company is in an investment phase rather than a scaling phase. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, as it reinvests all available resources, including its $100.41M cash hoard, into research and development activities to advance its therapeutic candidates. This reinvestment strategy is standard for biotechnology firms aiming to reach commercialization, prioritizing pipeline advancement over income distribution to shareholders. The overall growth and income profile is defined by a lack of current cash generation and a reliance on external capital markets to fund the transition from clinical trials to market entry.